Carisma Research Development from 2010 to 2026
| CARM Stock | 0.04 0.00 0.000002% |
Research Development | First Reported 2012-12-31 | Previous Quarter 2.4 M | Current Value 197 K | Quarterly Volatility 5.1 M |
Check Carisma Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Carisma Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 4 M, Interest Expense of 2 M or Selling General Administrative of 24.3 M, as well as many indicators such as Price To Sales Ratio of 0.97, Dividend Yield of 0.096 or Days Sales Outstanding of 58.17. Carisma financial statements analysis is a perfect complement when working with Carisma Therapeutics Valuation or Volatility modules.
Carisma | Research Development | Build AI portfolio with Carisma Stock |
Evaluating Carisma Therapeutics's Research Development across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Carisma Therapeutics's fundamental strength.
Latest Carisma Therapeutics' Research Development Growth Pattern
Below is the plot of the Research Development of Carisma Therapeutics over the last few years. It is Carisma Therapeutics' Research Development historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Carisma Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Research Development | 10 Years Trend |
|
Research Development |
| Timeline |
Carisma Research Development Regression Statistics
| Arithmetic Mean | 31,935,241 | |
| Geometric Mean | 24,704,579 | |
| Coefficient Of Variation | 74.59 | |
| Mean Deviation | 20,166,929 | |
| Median | 24,444,000 | |
| Standard Deviation | 23,821,397 | |
| Sample Variance | 567.5T | |
| Range | 64.7M | |
| R-Value | 0.85 | |
| Mean Square Error | 168.2T | |
| R-Squared | 0.72 | |
| Significance | 0.000016 | |
| Slope | 4,008,875 | |
| Total Sum of Squares | 9079.3T |
Carisma Research Development History
About Carisma Therapeutics Financial Statements
Carisma Therapeutics investors utilize fundamental indicators, such as Research Development, to predict how Carisma Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Research Development | 68.6 M | 72.1 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of Carisma Therapeutics Correlation against competitors. To learn how to invest in Carisma Stock, please use our How to Invest in Carisma Therapeutics guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Will Biotechnology sector continue expanding? Could Carisma diversify its offerings? Factors like these will boost the valuation of Carisma Therapeutics. Projected growth potential of Carisma fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Carisma Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share 0.2 | Revenue Per Share | Quarterly Revenue Growth 12.368 | Return On Assets | Return On Equity |
Understanding Carisma Therapeutics requires distinguishing between market price and book value, where the latter reflects Carisma's accounting equity. The concept of intrinsic value—what Carisma Therapeutics' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Carisma Therapeutics' price substantially above or below its fundamental value.
It's important to distinguish between Carisma Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Carisma Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Carisma Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.